NCT01546987 2026-03-06
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
Clinical Trials
16 trialsNCT01809691 2025-12-31
S1216
SWOG Cancer Research Network
Phase 3 Completed
NCT01816048 2019-12-09
NaF Positron Emission Tomography/Computed Tomography (PET/CT)Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastasis
University of Wisconsin, Madison
Phase 2 Terminated
NCT01084655 2019-07-30
Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer
Takeda
Phase 1/2 Completed
NCT01707966 2019-05-15
Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel Therapy
Swiss Cancer Institute
Phase 3 Completed
NCT01193257 2018-12-19
Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer.
Takeda
Phase 3 Completed
NCT02053311 2018-07-30
Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents
Swiss Cancer Institute
Phase 3 Withdrawn
NCT01666314 2018-03-20
Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Participants With Castration-Resistant Prostate Cancer
Takeda
Phase 1/2 Completed
NCT01866423 2017-08-31
Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
University of Southern California
Phase 2 Terminated
NCT03211052 2017-07-07
NEPTUNE
Queen Mary University of London
Phase 2 Terminated
NCT01193244 2017-05-17
Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Takeda
Phase 3 Completed
NCT01658527 2016-06-10
TAK-700 in Castration Resistant Prostate Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Withdrawn
NCT01549951 2016-06-01
Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer
Millennium Pharmaceuticals, Inc.
Phase 2 Completed
NCT00569153 2016-04-04
TAK-700
Millennium Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT01046916 2016-04-04
Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen
Millennium Pharmaceuticals, Inc.
Phase 2 Completed
NCT02054793 2014-07-23
Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itraconazole In Men With Castration-Resistant Prostate Cancer (CRPC)
Johns Hopkins University
Phase 1/2 Withdrawn